MDGSW (Medigus) Current Accrued Expense: $1.12 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGSW Medigus Ltd MDGSW
12 GF Score
Price $0.02
! 6 Warning Signs
View Full Analysis

What is Medigus Current Accrued Expense?

Medigus MDGSW 12 Current Accrued Expense is $1.12 Mil as of Dec. 2024. GuruFocus rates MDGSW with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.

Medigus's Current Accrued Expense for the quarter that ended in Dec. 2024 was $1.12 Mil.

Medigus's quarterly Current Accrued Expense declined from Dec. 2023 ($2.60 Mil) to Jun. 2024 ($2.14 Mil) and declined from Jun. 2024 ($2.14 Mil) to Dec. 2024 ($1.12 Mil).

Medigus's annual Current Accrued Expense increased from Dec. 2022 ($1.88 Mil) to Dec. 2023 ($2.60 Mil) but then declined from Dec. 2023 ($2.60 Mil) to Dec. 2024 ($1.12 Mil).

Medigus Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Medigus's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigus Current Accrued Expense Chart

Medigus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.25 1.56 1.88 2.60 1.12

Medigus Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.88 3.65 2.60 2.14 1.12
MDGSW
12GF Score
Medigus Ltd MDGSW
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigus Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.12 Mil mean?
Medigus (MDGSW) has a Current Accrued Expense of $1.12 Mil as of Dec. 2024. Current Accrued Expense records the total amount of accrued expenses. View historical data on Medigus and its competitors.
Is Medigus' Current Accrued Expense too high?
Medigus' current Current Accrued Expense is $1.12 Mil. Overall, Medigus has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigus' Current Accrued Expense compare to RMSL and HSDT?
Medigus' Current Accrued Expense of $1.12 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Medigus and its competitors. Medigus's current Current Accrued Expense is $1.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigus stock overvalued right now?
Medigus (MDGSW) has a current Current Accrued Expense of $1.12 Mil. The current Current Accrued Expense is $1.12 Mil. Medigus' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Medigus (MDGSW), the current Current Accrued Expense is $1.12 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigus Business Description

Address 10 Hanechoshet Street, 4th Floor, Tel Aviv, ISR, 6971072
Xylo Technologies Ltd is an Israel-based medical device company. The company is engaged in the development, manufacturing, and marketing of direct vision systems for minimally invasive medical procedures and safety systems for drones and the electric vehicle (EV) sector. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incision-less treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company operates in four segments are: Corporate, Online advertising & internet traffic routing, Online event management, real-estate and electronics. The company's geographical segments include USA, Europe, Great Britain, Israel, Canada, Asia and others.
12GF Score

Get the complete analysis for MDGSW

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price